Bladder Cancer Canada Report issue

Foundation Phase 1 Phase 3

Organization Overview

First Clinical Trial
2017
NCT03266900
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Bladder Cancer Canada

Active Ingredients

Drugs in Phase 3 Trials (3)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

gemcitabine (gemzar) (1 trial)

Drugs in Phase 1 Trials (1)

bacille calmette-guerin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Transitional Cell (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 4